Endo International plc announced that Endo’s wholly-owned indirect subsidiary, Beta Acquisition Corp., has commenced its previously announced tender offer to acquire all of the outstanding shares of common stock, par value $0.001 per share of BioSpecifics Technologies Corp., at a price of $88.50 per Share, net to the holder in cash, without interest and less any applicable withholding taxes.
November 2, 2020
· 7 min read